Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice-Reference-Cited by-同舟云学术

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice

Published:2018-04-19 Issue:9 Volume:97 Page:1577-1580
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Breccia Massimo^ORCID,Abruzzese Elisabetta,Castagnetti Fausto,Bonifacio Massimiliano,Gangemi Domenica,Sorà Federica,Iurlo Alessandra,Luciano Luigiana,Gozzini Antonella,Gentile Massimo,Bocchia Monica,Luzi Debora,Maggi Alessandro,Sgherza Nicola,Isidori Alessandro,Crugnola Monica,Pregno Patrizia,Scortechini Anna Rita,Capodanno Isabella,Pizzuti Michele,Foà Robin

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3337-2/fulltext.html

Reference8 articles.

1. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators (2013) PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New Engl J Med 369:1783–1796

2. Cortes JE, Kim DW, Pinilla-Ibarz J, et al (2014) Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 124: abstract 3135

3. Poch Martell M, Sibai H, Deotare U, Lipton JH (2016) Ponatinib in the therapy of chronic myeloid leukemia. Exp Rev Hematol 9:923–932

4. Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M (2017) Identification, prevention and management of cardiovascular risk in chronic myeloid leukemia patients candidate to ponatinib: an expert opinion. Ann Hematol 96:549–558

5. Muller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G (2017) Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol 120:52–59

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies;Hematology, Transfusion and Cell Therapy;2024-08

2. Progress in the study of autophagy-related proteins affecting resistance to chemotherapeutic drugs in leukemia;Frontiers in Cell and Developmental Biology;2024-06-03

3. Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors;Blood;2024-03-07

4. Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia;Journal of Clinical Medicine;2024-01-03

5. Real-world Management of CML: Outcomes and Treatment Patterns;Current Hematologic Malignancy Reports;2023-07-03